Therapy News and Research

RSS

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it will sponsor a clinical study comparing the effects of ActiPatch® Therapy to Tylenol® for the treatment of muscle pain and soreness.

24 Aug 2009

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

24 Aug 2009

Osteologix announces receipt of Decision to Grant a Patent from JPO for NB S101 osteoporosis drug candidate

Osteologix, Inc. (OTCBB:OLGX) today announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for Application Number 2006-504379: "Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts". The patent claims cover the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the Company's lead osteoporosis drug candidate.

24 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

$1.1 million funds will help make critical enhancements to Integrated Medical Systems' MedEx 1000 system

Integrated Medical Systems, Inc., a medical technology systems integrator transforming critical care, announced that it has received $1.1 million in funding from the U.S. Department of Defense for additional enhancements of the company's MedEx 1000(TM) "suitcase" intensive care unit (ICU).

24 Aug 2009

Synexus acquires three more clinical trial centres in Poland

Synexus’ expansion in Central and Eastern Europe has been boosted with the acquisition of three more clinical trial centres in Poland.

From AES - Accelerated Enrollment Solutions 24 Aug 2009

PLoS Medicine's editors to eventually stamp ghostwriting

Today, PLoS Medicine places in the public domain all documents - around 1500 - released after the journal and The New York Times intervention in the Prempro case. The documents, are available on the PLoS Medicine website, and are uploaded in the form that PLoS received them from the court.

24 Aug 2009

Two key circuits for controlling the cell's ability identified by UCSF researchers

UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.

24 Aug 2009

Recent releases: limiting corruption; mental health; U.S. global health policies; non-physician administered ARV; African health ministers

A Lancet Infectious Diseases Reflection and Reaction piece says while PEPFAR's "investment of over US$228 million into Mozambique in 2008 alone" resulted in "an exponential increase in the number of people on" ARVs and boosted prevention programs, "[t]here is more money available for HIV/AIDS than can reasonably be spent, especially given Mozambique's poor infrastructure and large geographical area. Unfortunately, one side-effect has been an associated increase in corruption." To maximize aid money and limit corruption, "careful and creative resource management will be needed," the author concludes (Johnson, 9/09).

24 Aug 2009

Tiny filaments extending from cells may play a role in common malignant brain tumors

UCSF scientists have discovered that a tiny filament extending from cells, until recently regarded as a remnant of evolution, may play a role in the most common malignant brain tumor in children.

24 Aug 2009

Study reveals high cholestrol as a cause of cardiac arrhythmias

Cholesterol can affect the flow of the electrical currents that generate the heart beat, according to a study from two UBC cardiovascular researchers funded by the Heart and Stroke Foundation of BC & Yukon. The research team has just published the important discovery about the causes of cardiac arrhythmias (abnormal heartbeats) in one of the world's leading scientific journals.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.

24 Aug 2009

Gene discovery unveils a new protein that protects against hearing loss

Discovery of a deafness-causing gene defect in mice has helped identify a new protein that protects sensory cells in the ear, according to a study by University of Iowa and Kansas State University researchers. The findings appear in the August 21 issue of the open-access journal PLoS Genetics.

24 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

Discovery of mutation in AIP gene associated with acromegaly

An indigenous family living in a mountainous area of Malaysian Borneo helped Van Andel Research Institute (VARI) researchers to discover information about genetic mutations associated with acromegaly, a form of gigantism that often results in enlarged hands, feet, and facial features.

24 Aug 2009

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

22 Aug 2009

MarrowXpress System used for isolation and retrieval of bone marrow-derived adult stem cells

Celling Technologies collaborated with innovative cell processing expert, ThermoGenesis Corp., to deliver the most sophisticated point of care cell separation device on the market. The innovative MarrowXpress(TM) (MXP(TM)) System defines a new standard for isolation and retrieval of bone marrow-derived adult stem cells.

21 Aug 2009

Therapy News and Research

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Retigabine's Phase IIa clinical trial preliminary results announced

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

Osteologix announces receipt of Decision to Grant a Patent from JPO for NB S101 osteoporosis drug candidate

Study reveals that increased neurostimulation market offers growth for device industries

$1.1 million funds will help make critical enhancements to Integrated Medical Systems' MedEx 1000 system

Synexus acquires three more clinical trial centres in Poland

PLoS Medicine's editors to eventually stamp ghostwriting

Two key circuits for controlling the cell's ability identified by UCSF researchers

Recent releases: limiting corruption; mental health; U.S. global health policies; non-physician administered ARV; African health ministers

Tiny filaments extending from cells may play a role in common malignant brain tumors

Study reveals high cholestrol as a cause of cardiac arrhythmias

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Gene discovery unveils a new protein that protects against hearing loss

Lundbeck to launch Sabril in the US following FDA's NDA approval

Discovery of mutation in AIP gene associated with acromegaly

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

MarrowXpress System used for isolation and retrieval of bone marrow-derived adult stem cells

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News